Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Hahn

Showing results (811-820 of 866) with videos related to

Pageof 87
Sort By:
Science (New York, N.Y.)|November 29, 2014
Mosquito genomics. Extensive introgression in a malaria vector species complex revealed by phylogenomicsMichael C Fontaine, James B Pease, Aaron Steele, et al.
Cancer|February 11, 2026
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panelRana R McKay, Benjamin L Maughan, Alicia K Morgans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on EnzalutamideWassim Abida, Andrew W Hahn, Neal Shore, et al.
BJU International|June 5, 2024
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlatesAndrew W Hahn, Ganiraju C Manyam, Brian F Chapin, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
European Urology Focus|March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint TherapyAndrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 19, 2024
Endothelial-specific CXCL12 regulates neovascularization during tissue repair and tumor progressionAndrew C Hostler, William W Hahn, Michael S Hu, et al.
AIDS and Behavior|September 28, 2025
Differences in Methamphetamine Use, Self-Reported Impact, and HIV-Related Outcomes by Gender and Sexual Orientation in a Multisite U.S. Cohort of People with HIV in CareR J Fredericksen, R M Nance, L N Drumright, et al.
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2024
Body composition as a determinant of the therapeutic index with androgen signaling inhibitionAndrew W Hahn, Rebecca S Tidwell, Patrick G Pilie, et al.
Pageof 87

Showing results (811-820 of 866) with videos related to

Sort By:
Pageof 87
Science (New York, N.Y.)|November 29, 2014
Mosquito genomics. Extensive introgression in a malaria vector species complex revealed by phylogenomicsMichael C Fontaine, James B Pease, Aaron Steele, et al.
Cancer|February 11, 2026
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panelRana R McKay, Benjamin L Maughan, Alicia K Morgans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on EnzalutamideWassim Abida, Andrew W Hahn, Neal Shore, et al.
BJU International|June 5, 2024
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlatesAndrew W Hahn, Ganiraju C Manyam, Brian F Chapin, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
European Urology Focus|March 2, 2023
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint TherapyAndrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 19, 2024
Endothelial-specific CXCL12 regulates neovascularization during tissue repair and tumor progressionAndrew C Hostler, William W Hahn, Michael S Hu, et al.
AIDS and Behavior|September 28, 2025
Differences in Methamphetamine Use, Self-Reported Impact, and HIV-Related Outcomes by Gender and Sexual Orientation in a Multisite U.S. Cohort of People with HIV in CareR J Fredericksen, R M Nance, L N Drumright, et al.
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2024
Body composition as a determinant of the therapeutic index with androgen signaling inhibitionAndrew W Hahn, Rebecca S Tidwell, Patrick G Pilie, et al.
Pageof 87